Pretreatment with Carpolobia lutea ethanol extract prevents schizophrenia-like behavior in mice models of psychosis
No Thumbnail Available
Date
2022-06-03
Journal Title
Journal ISSN
Volume Title
Publisher
Journal of Ethnopharmacology3 June 2022
Abstract
Ethnopharmacological relevance: Carpolobia lutea decoction is widely used as a phytotherapeutic against central
nervous system-related disorders including insomnia, migraine headache, and mental illness in West and Central
Tropical Africa.
Aim: This study was designed to investigate the antipsychotic activity of Carpolobia lutea (EECL) in mice models
of psychosis.
Methods: Male Swiss mice (n = 5/group) were given EECL (100, 200, 400, and 800 mg/kg), haloperidol (1 mg/
kg), clozapine (5 mg/kg) and vehicle (10 mL/kg) orally before amphetamine (5 mg/kg)-induced hyper-
locomotion and stereotypy, apomorphine (2 mg/kg)-induced stereotypy, or ketamine (10, 30, and 100 mg/kg)-
induced hyperlocomotion, enhancement of immobility and cognitive impairment.
Results: EECL (200, 400, and 800 mg/kg) prevented amphetamine- and apomorphine-induced stereotypies, as
well as reduced hyperlocomotion induced by amphetamine and ketamine, all of which are predictors of positive
symptoms. Regardless of the dose administered, EECL prevented the index of negative symptoms induced by
ketamine. Furthermore, higher doses of EECL (400 and 800 mg/kg) also prevented ketamine-induced cognitive
impairment, a behavioral phenotype of cognitive symptoms.
Conclusion: Pretreatment with EECL demonstrated antipsychotic activity in mice, preventing amphetamine-,
apomorphine-, and ketamine-induced schizophrenia-like symptoms, with 800 mg/kg being the most effective
dose.
Description
Keywords
Citation
Amphetamine Apomorphine Carpolobia lutea Ketamine Schizophrenia